WO2014016613A3 - Type b lantibiotic nvb302 for the treatment of c. difficile infection - Google Patents

Type b lantibiotic nvb302 for the treatment of c. difficile infection Download PDF

Info

Publication number
WO2014016613A3
WO2014016613A3 PCT/GB2013/052010 GB2013052010W WO2014016613A3 WO 2014016613 A3 WO2014016613 A3 WO 2014016613A3 GB 2013052010 W GB2013052010 W GB 2013052010W WO 2014016613 A3 WO2014016613 A3 WO 2014016613A3
Authority
WO
WIPO (PCT)
Prior art keywords
difficile infection
nvb302
lantibiotic
treatment
type
Prior art date
Application number
PCT/GB2013/052010
Other languages
French (fr)
Other versions
WO2014016613A2 (en
Inventor
Michael John Dawson
Original Assignee
Novacta Biosystems Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Limited filed Critical Novacta Biosystems Limited
Publication of WO2014016613A2 publication Critical patent/WO2014016613A2/en
Publication of WO2014016613A3 publication Critical patent/WO2014016613A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The inventions provides a method of treating a human subject for C. difficile infection comprising administering orally a therapeutically effective dose of an antibiotic (for example 50 mg to 750 mg) which is selective for C. difficile over Gram-negative bacteria which are 5 components of natural healthy gut flora, wherein the average systemic plasma level of the antibiotic and any metabolites thereof does not exceed 5 ng/mL, for example is 4, 3, or 2 ng/mL or less.
PCT/GB2013/052010 2012-07-27 2013-07-26 The use of type-b lantibiotic-based compounds having antimicrobial activity WO2014016613A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1213434.2A GB201213434D0 (en) 2012-07-27 2012-07-27 The use of type-B lantibiotic-based compounds having antimicrobial activity
GB1213434.2 2012-07-27

Publications (2)

Publication Number Publication Date
WO2014016613A2 WO2014016613A2 (en) 2014-01-30
WO2014016613A3 true WO2014016613A3 (en) 2014-04-10

Family

ID=46881295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/052010 WO2014016613A2 (en) 2012-07-27 2013-07-26 The use of type-b lantibiotic-based compounds having antimicrobial activity

Country Status (2)

Country Link
GB (1) GB201213434D0 (en)
WO (1) WO2014016613A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010763A1 (en) * 2007-07-18 2009-01-22 Novacta Biosystems Limited The use of type-b lantibiotic-based compounds having antimicrobial activity
WO2009010765A2 (en) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Lantibiotic-based compounds having antimicrobial activity
WO2010082018A1 (en) * 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
WO2012007711A1 (en) * 2010-07-14 2012-01-19 Novacta Biosystems Limited Formulation comprising a type b lantibiotic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202008002206U1 (en) 2008-02-15 2009-06-25 Voss Automotive Gmbh Multiple plug-in coupling for media lines
KR101076603B1 (en) 2008-07-16 2011-10-26 옵티시스 주식회사 Optical communication module for optical wavelength division multipexing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009010763A1 (en) * 2007-07-18 2009-01-22 Novacta Biosystems Limited The use of type-b lantibiotic-based compounds having antimicrobial activity
WO2009010765A2 (en) * 2007-07-18 2009-01-22 Novacta Biosystems Limited Lantibiotic-based compounds having antimicrobial activity
WO2010082018A1 (en) * 2009-01-14 2010-07-22 Novacta Biosystems Limited Deoxyactagardine derivatives
WO2012007711A1 (en) * 2010-07-14 2012-01-19 Novacta Biosystems Limited Formulation comprising a type b lantibiotic

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "First-in-man study", 13 December 2011 (2011-12-13), pages 1 - 1, XP055089334, Retrieved from the Internet <URL:http://www.european-biotechnology-news.com/news/messages-archive/archive/article/first-in-man-study-1.html> [retrieved on 20131120] *
ANONYMOUS: "ISRCTN40071144 - Assessment of the safety and distribution of NVB302 in healthy volunteers", 23 October 2012 (2012-10-23), pages 1 - 3, XP055089342, Retrieved from the Internet <URL:http://www.controlled-trials.com/ISRCTN40071144/ISRCTN40071144> [retrieved on 20131120] *
ANONYMOUS: "New antibiotic compound enters phase I clinical trial", 3 November 2011 (2011-11-03), pages 1 - 2, XP055089306, Retrieved from the Internet <URL:http://www.wellcome.ac.uk/News/2011/News/WTVM053339.htm> [retrieved on 20131120] *
COLE P ET AL: "ANTI-INFECTIVE INNOVATIONS: HIGHLIGHTS FROM THE 49TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC)", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 34, no. 12, 1 December 2009 (2009-12-01), pages 1005 - 1028, XP002678682, ISSN: 0377-8282 *
S N WADMAN ET AL: "F1-1517 - NVB302: A Narrow Spectrum Antibiotic under Development for the Treatment of Clostridium difficile Infection", 14 September 2009 (2009-09-14), pages 1 - 2, XP055089121, Retrieved from the Internet <URL:http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2392&sKey=b3a51521-cc31-42fb-8524-327ffd7e3019&cKey=ea9e99fe-198d-4f9a-87aa-053d4767e6bb> [retrieved on 20131119] *
S. D. BAINES ET AL: "F1-1519 - NVB302: In Vitro Activity against Clostridium difficile", 14 September 2009 (2009-09-14), pages 1 - 2, XP055089127, Retrieved from the Internet <URL:http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2392&sKey=b3a51521-cc31-42fb-8524-327ffd7e3019&cKey=35adbb63-88d5-438d-b111-5f864ae0c884> [retrieved on 20131119] *
S. N. WADMAN ET AL: "F1-1518 - NVB302: In vitro Activity against Clostridium difficile and Intestinal Strains of Anaerobic Bacteria", 14 September 2009 (2009-09-14), pages 1 - 2, XP055089124, Retrieved from the Internet <URL:http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2392&sKey=b3a51521-cc31-42fb-8524-327ffd7e3019&cKey=b6f9c21c-768c-445d-a91e-4b65932517a9> [retrieved on 20131119] *
S. N. WADMAN: "F1-1520 - NVB302: Gastro-Intestinal S tability and In Vivo Activity in the Hamster Cecitis Model for Clostridium difficile Infection", 14 September 2009 (2009-09-14), pages 1 - 2, XP055089128, Retrieved from the Internet <URL:http://www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=2392&sKey=b3a51521-cc31-42fb-8524-327ffd7e3019&cKey=9ee77847-e116-47c0-82a4-5916b48bfd21> [retrieved on 20131119] *
STEPHEN PARKER: "Novacta Biosystems Limited completes Phase I study of NVB302 against C. difficile infection in healthy volunteers", 6 August 2012 (2012-08-06), pages 1 - 3, XP055089346, Retrieved from the Internet <URL:http://www.celticpharmaholdings.com/component/k2/item/5-novacta-biosystems-limited-completes-phase-i-study-of-nvb302-against-c-difficile-infection-in-healthy-volunteers> [retrieved on 20131120] *

Also Published As

Publication number Publication date
GB201213434D0 (en) 2012-09-12
WO2014016613A2 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX2018001435A (en) Methods of treating lennox-gastaut syndrome using fenfluramine.
IL268960A (en) 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (thip) for use in the treatment of fragile x syndrome
PH12016500619A1 (en) Dry powder inhaler
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington&#39;s disease
NZ713615A (en) Methods for treating bacterial infections
MX369385B (en) Products for healing of tissue wounds.
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2019013279A (en) Methods of treating doose syndrome using fenfluramine.
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2013100567A8 (en) Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
MX344787B (en) Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders.
WO2016133903A3 (en) Combination therapy for cancer treatment
MY174010A (en) Device for extracorporeal blood treatment
MX2018004309A (en) Combination therapies for treating cancer.
MX2013003060A (en) Combination therapy for treating hcv infection.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2017009122A (en) Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat.
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
WO2012177075A3 (en) Composition containing antibiotics and lysophosphatidylcholine for boosting immunity or treatment of bacterial infections
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019002894A (en) Combinations with a backbone-cyclized peptide.
MX370957B (en) Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis.
WO2014016613A3 (en) Type b lantibiotic nvb302 for the treatment of c. difficile infection
NZ703729A (en) Combinations with a backbone-cyclized peptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13747683

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13747683

Country of ref document: EP

Kind code of ref document: A2